BDBM417021 (+)-5-(1-amino-1-(3-(1-(3-(aminomethyl)phenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamido)-4-fluorophenyl)-3-cyclopropylpropyl)picolinamide::US10329260, Compound 221i::US10633345, Compound 221i::US10689346, Compound 221i::US11203574, Compound 221i::US11230530, Compound 221i::US11685721, Compound 221i::US11708332, Compound 221i

SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccc(nc1)C(N)=O)C(F)(F)F

InChI Key InChIKey=IQWHGFSUUIEJQU-UHFFFAOYSA-N

Data  8 KI  2 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 10 hits for monomerid = 417021   

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM417021((+)-5-(1-amino-1-(3-(1-(3-(aminomethyl)phenyl)-3-(...)
Affinity DataIC50: 1.70nMAssay Description:Inhibition of endogenous human plasma kallikrein using Z-Phe-Arg-AMC.HCl as substrate measured after 5 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM417021((+)-5-(1-amino-1-(3-(1-(3-(aminomethyl)phenyl)-3-(...)
Affinity DataIC50: 2.30nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM417021((+)-5-(1-amino-1-(3-(1-(3-(aminomethyl)phenyl)-3-(...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM417021((+)-5-(1-amino-1-(3-(1-(3-(aminomethyl)phenyl)-3-(...)
Affinity DataKi:  25.1nMAssay Description:Plasma kallikrein activity assay. The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM417021((+)-5-(1-amino-1-(3-(1-(3-(aminomethyl)phenyl)-3-(...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM417021((+)-5-(1-amino-1-(3-(1-(3-(aminomethyl)phenyl)-3-(...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM417021((+)-5-(1-amino-1-(3-(1-(3-(aminomethyl)phenyl)-3-(...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM417021((+)-5-(1-amino-1-(3-(1-(3-(aminomethyl)phenyl)-3-(...)
Affinity DataKi:  25.1nMAssay Description:Plasma kallikrein activity assay. The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM417021((+)-5-(1-amino-1-(3-(1-(3-(aminomethyl)phenyl)-3-(...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/17/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM417021((+)-5-(1-amino-1-(3-(1-(3-(aminomethyl)phenyl)-3-(...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
US Patent